PRMT5 and astrocytoma (excluding glioblastoma): There is no clear evidence on whether IDH mutation or MGMT promoter methylation can affect the anti-tumor activity of PRMT5 in G4 astrocytoma when used in conjunction with other chemotherapeutic agents.